STAT Plus In disappointment Bristol pulls FDA application for Opdivo combination in lung cancer

STAT Plus: In disappointment, Bristol pulls FDA application for Opdivo combination in lung cancer

In another setback in the lucrative lung cancer market, Bristol-Myers Squibb is withdrawing its application with the FDA to use its cancer immunotherapy blockbuster, Opdivo

More From BioPortfolio on "STAT Plus: In disappointment, Bristol pulls FDA application for Opdivo combination in lung cancer"